Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 5/20 | 0.49 |
| ▸ | FLT4 | P35916 | 5/20 | 0.49 |
| ▸ | KDR | P35968 | 5/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 6/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16990703 | 0.93 | MAPK14 (0.52) | FLT1FLT4KDRGSK3BRAF1 | |
| SCHEMBL16990621 | 0.93 | GSK3B (0.46) | FLT1FLT4KDRGSK3BHTR2A | |
| SCHEMBL15574776 | 0.91 | GSK3B (0.54) | FLT1FLT4KDRGSK3BHTR2A | |
| SCHEMBL169223 | 0.89 | GSK3B (0.63) | FLT1FLT4KDRGSK3BHTR2A | |
| SCHEMBL16990625 | 0.85 | RAF1 (0.56) | FLT1FLT4KDRGSK3BHTR2A | |
| SCHEMBL16990708 | 0.85 | RAF1 (0.58) | KDRGSK3BRAF1BRAFTRPV1 | |
| SCHEMBL16990689 | 0.83 | RAF1 (0.50) | GSK3BRAF1BRAFTRPV1 | |
| SCHEMBL171225 | 0.83 | GSK3B (0.61) | FLT1FLT4KDRGSK3BHTR2A | |
| SCHEMBL170834 | 0.83 | GSK3B (0.61) | FLT1FLT4KDRGSK3BHTR2A | |
| SCHEMBL169266 | 0.82 | GSK3B (0.62) | FLT1FLT4KDRGSK3BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | FLT1 2139/4885FLT4 2680/4885KDR 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.